OpenAI and Anthropic put £200 million into the UK’s new biological threat lab
Key Points
- UK launches AI Biosecurity Lab with up to £300 million in backing
- OpenAI and Anthropic each commit up to £100 million in credits and access
- Government contributes £100 million in funding to the new lab
- Lab will focus on early threat detection and faster vaccine development
- Google DeepMind and Basecamp Research join as research partners
OpenAI and Anthropic have committed up to £200 million to the UK’s new AI Biosecurity Lab. The Cabinet Office announced the AI Biosecurity Lab (AIBL) on Saturday (24 October), and described it as the world’s first dedicated AI biosecurity organisation.
The government is providing £100 million in funding, bringing the total backing for the lab to up to £300 million. AIBL will use frontier AI to help the UK understand, prevent, detect and respond to biological threats, building on the country’s existing Biological Security Strategy.
The government said that AI advances open up major opportunities for scientific discovery but also change the nature of biological risk. It added that increasingly capable AI systems could lower the barriers to harmful activity.
The commitments from the two AI companies include:
- OpenAI: £100 million in compute and model credits, plus trusted access to its most capable relevant models through its Rosalind Biodefense programme
- Anthropic: up to £100 million in model credits, trusted model access and dedicated technical support
Google DeepMind and UK AI life sciences company Basecamp Research will also partner with the lab on research collaborations and AI tools for science.
Basecamp Research will give AIBL access to its AI-biology models, capabilities and technical expertise to tackle priority biosecurity challenges.
Google DeepMind scientists and biosecurity experts will work with AIBL on research, and the company will look to provide trusted access to its frontier Gemini and specialised science models.
The lab’s initial work will focus on two areas:
- Early detection of emerging biological threats
- Faster development of vaccines, treatments and other medical countermeasures
AIBL will work with the UK’s national biosecurity centres and its life sciences industry to help the UK and other countries respond faster to disease outbreaks.
The lab will operate as an independent, non-profit organisation, and the government compared its setup to the AI Security Institute.
The government said AIBL will attract leading industry and academic talent and move with the speed and focus of a frontier AI and biology company.
A scientific advisory committee drawing on academia, industry and the third sector will support the lab, with the government set to share further details in due course.
AIBL forms part of a wider National AI Biosecurity Initiative, which brings together the UK Health Security Agency (UKHSA), the Animal and Plant Health Agency (APHA) and the Defence Science and Technology Laboratory (Dstl).
The lab will also work with the Medicines and Healthcare products Regulatory Agency (MHRA) to prepare for health emergencies and inform how the UK regulates AI-designed medicines.
The government said it intends to fund AIBL through a mix of public and philanthropic money over time.
